Prescribing proton pump inhibitors: Is it time to pause and rethink?

Drugs

Volumn 72, Issue 4, 2012, Pages 437-445

  Vakil, Nimish ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Alendronic acid; Calcium metabolism; Colon cancer; Dexlansoprazole; Esomeprazole; Gastric cancer; Gastro oesophageal reflux; Omeprazole; Proton pump inhibitors

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; CYANOCOBALAMIN; DIGOXIN; ESOMEPRAZOLE; HEMOGLOBIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; LOOP DIURETIC AGENT; MAGNESIUM; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; THIAZIDE DIURETIC AGENT;

ARM FRACTURE; BARRETT ESOPHAGUS; BONE DENSITOMETRY; CANCER RISK; CARCINOGENESIS; CLINICAL PRACTICE; COLON CANCER; COMMUNITY ACQUIRED PNEUMONIA; CONVULSION; CORPUS GASTRITIS; CYANOCOBALAMIN DEFICIENCY; DRUG COST; DRUG DOSE REDUCTION; DRUG SAFETY; DYSPEPSIA; ESOPHAGEAL ADENOCARCINOMA; FRACTURE; FRAGILITY FRACTURE; GASTRITIS; GASTROESOPHAGEAL REFLUX; HEARTBURN; HIP FRACTURE; HUMAN; HYPERGASTRINEMIA; HYPOMAGNESEMIA; INFECTION RISK; INTERSTITIAL NEPHRITIS; INTESTINE INFECTION; IRON DEFICIENCY ANEMIA; MAGNESIUM BLOOD LEVEL; MENTAL DISEASE; OSTEOPOROSIS; PRESCRIPTION; REBOUND; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; SPINE FRACTURE; STOMACH ATROPHY; STOMACH CANCER; STOMACH DISEASE; STOMACH POLYP; TETANY; TREATMENT DURATION; WRIST FRACTURE;

GASTROESOPHAGEAL REFLUX; HUMANS; PROTON PUMP INHIBITORS; RISK ASSESSMENT; TIME FACTORS;

EID: 84857288531     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11599320-000000000-00000     Document Type: Review

References (58)

1. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care 2010 Sep; 16 (9): e228-34
2. Godman B, Sakshaug S, Berg C, et al. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev Pharmacoecon Outcomes Res 2011 Feb; 11 (1): 121-9
3. IMS. IMS health reports US prescription sales grew 5.1 percent in 2009, to $300.3 billion [media release; online]. Available from URL: http://www.imshealth.com/portal/site/imshealth/menuitem. a46c6d4df3db4b3d88f611019418c22a/?vgnextoid= d690a27e9d5b7210VgnVCM100000ed152ca2RC RD&vgnextchannel= 41a67900b55a5110VgnVCM100000718 12ca2RCRD&vgnextfmt=default [Accessed 2011 Oct 1]
4. El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol 2007; 5 (1): 17-26 (Pubitemid 46096825)
5. Dubois RW, Aguilar D, Fass R, et al. Consequences of frequent nocturnal gastro-oesophageal reflux disease among employed adults: symptom severity, quality of life, and work productivity. Aliment Pharmacol Ther 2007; 25 (4): 487-500 (Pubitemid 46184463)
6. Farup C, Kleinman L, Sloan S, et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med 2001; 161 (1): 45-52 (Pubitemid 32052142)
7. Jung HK. Epidemiology of gastroesophageal reflux disease in Asia: a systematic review. J Neurogastroenterol Motil 2011 Jan; 17 (1): 14-27
8. Lagergren J, Bergström R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999 Mar 18; 340 (11): 825-31 (Pubitemid 29142625)
9. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 2008 Aug 20; 100 (16): 1184-7
10. Nguyen DM, El-Serag HB, Henderson L, et al. Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2009 Dec; 7 (12): 1299-304
11. Guda NM, Vakil N. Proton pump inhibitors and the time trends for esophageal dilation. Am J Gastroenterol 2004 May; 99 (5): 797-800 (Pubitemid 39090202)
12. El-Serag HB. Temporal trends in new and recurrent esophageal strictures in Department of Veterans Affairs. Am J Gastroenterol 2006 Aug; 101 (8): 1727-33 (Pubitemid 44166578)
13. Hoorn EJ, van der Hoek J, de Man RA, et al. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 2010 Jul; 56 (1): 112-6
14. Cundy T, Dissanayake A. Severe hypomagnesaemia in longterm users of proton-pump inhibitors. Clin Endocrinol (Oxf) 2008; 69 (2): 338-41 (Pubitemid 352009025)
15. Mackay JD, Bladon PT. Hypomagnesaemia due to protonpump inhibitor therapy: a clinical case series. QJM 2010 Jun; 103 (6): 387-95
16. Schlingmann KP, Weber S, Peters M, et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6,a new member of the TRPM gene family. Nat Genet 2002; 31: 166-70
17. Hansen KE, Jones AN, Lindstrom MJ, et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res 2010 Dec; 25 (12): 2786-95
18. Wright MJ, Sullivan RR, Gaffney-Stomberg E, et al. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res 2010 Oct; 25 (10): 2205-11
19. O'Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005 Jul; 118 (7): 778-81 (Pubitemid 40897665)
20. Targownik LE, Lix LM, Leung S, et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010 Mar; 138 (3): 896-904
21. Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008 Oct; 83 (4): 251-9
22. Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med 2010 May 10; 170 (9): 765-71
23. Targownik LE, Leslie WD. The relationship among proton pump inhibitors, bone disease and fracture. Expert Opin Drug Saf 2011 Nov; 10 (6): 901-12
24. Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2011 Jul; 106 (7): 1209-18
25. Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone 2011 Apr 1; 48 (4): 768-76
26. Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med 2011; 171 (11): 998-1004
27. Poulsen AH, Christensen S, McLaughlin JK, et al. Proton pump inhibitors and risk of gastric cancer: a populationbased cohort study. Br J Cancer 2009 May 5; 100 (9): 1503-7
28. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661-9 (Pubitemid 30171615)
29. Schenk BE, Kuipers EJ, Nelis GF, et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 2000 May; 46 (5): 615-21 (Pubitemid 30305777)
30. Lundell L, Miettinen P, Myrvold HE, et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Gastroenterology 1999 Aug; 117 (2): 319-26 (Pubitemid 29352939)
31. Lundell L, Havu N, Miettinen P, et al., Nordic GERD Study Group. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther 2006 Mar 1; 23 (5): 639-4
32. van Soest EM, van Rossum LGM, Dieleman JP, et al. Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol 2008; 103: 966-73 (Pubitemid 351501082)
33. RobertsonDJ, LarssonH, Friis S, et al. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case control study. Gastroenterology 2007; 133: 755-60 (Pubitemid 47385871)
34. Stewart CA, Termanini B, Sutliff VE, et al. Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther 1998; 12: 83-98 (Pubitemid 28057410)
35. Sarzynski E, Puttarajappa C, Xie Y, et al.Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig Dis Sci 2011 Aug; 56 (8): 2349-53
36. Hutchinson C, Geissler CA, Powell JJ, et al. Proton pump inhibitors suppress absorption of dietary non-heme iron in hereditary hemochromatosis. Gut 2007; 56: 1291-5 (Pubitemid 47300432)
37. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004; 57: 422-8 (Pubitemid 38609284)
38. den Elzen WPJ, Groeneveld Y, de Ruijter W, et al. Longterm use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther 2008; 27: 491-7 (Pubitemid 351300856)
39. Geevasinga N, Coleman PL, Webster AC, et al. Proton pump inhibitors and acute interstitial nephritis. Clin Gastroenterol Hepatol 2006 May; 4 (5): 597-604
40. Vakil N. Acid inhibition and infections outside the gastrointestinal tract. Am J Gastroenterol 2009; 104: S10-6
41. Laheij RJF, Sturkenboom MCJM, Hassing R-J, et al. Risk of community-acquired pneumonia and use of gastric acidsuppressive drugs. JAMA 2004; 292: 1955-60 (Pubitemid 39411203)
42. Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007; 167: 950-5 (Pubitemid 46762758)
43. Sarkar M, Hennessy S, Yang YX, et al. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008; 149: 391-8
44. Dublin S, Walker RL, Jackson ML, et al. Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study. Pharmacoepidemiol Drug Saf 2010 Aug; 19 (8): 792-802
45. Yang YX, Metz D. Safety of proton pump exposure. Gastroenterology 2010; 139: 1115-27
46. Redelmeier DA, McAlister FA, Kandel CE, et al. Postoperative pneumonia in elderly patients receiving acid suppressants: a retrospective cohort analysis. BMJ 2010; 340: c2608
47. Dial S. Proton pump inhibitor use and enteric infections. Am J Gastroenterol 2009; 104: S10-6
48. Paredes-Sabja D, Bond C, Carman RJ, et al. Germination of spores of Clostridium difficile strains, including isolates from a hospital outbreak of Clostridium difficile-associated disease (CDAD). Microbiology 2008; 154: 2241-50
49. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007 Sep; 102 (9): 2047-56 (Pubitemid 47301504)
50. Reimer C, Sondergaard B, Hilsted L, et al. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009; 137: 80-7
51. Juul-Hansen P, Rydning A. Clinical and pathophysiological consequences of on-demand treatment with PPI in endoscopy-negative reflux disease: is rebound hypersecretion of acid a problem? Scand J Gastroenterol 2011 Apr; 46 (4): 398-405
52. Metz DC, Pilmer BL, Han C, et al. Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data. Am J Gastroenterol 2011 Nov; 106 (11): 1953-60
53. Niv Y. Gradual cessation of proton pump inhibitor (PPI) treatment may prevent rebound acid secretion, measured by the alkaline tide method, in dyspepsia and reflux patients. Med Hypotheses 2011 Sep; 77 (3): 451-2
54. Batuwitage BT, Kingham JG, Morgan NE, et al. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007 Jan; 83 (975): 66-8
55. Ramirez E, Lei SH, Borobia AM, et al. Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital. Curr Clin Pharmacol 2010 Nov; 5 (4): 288-97
56. Zink DA, PohlmanM, BarnesM, et al. Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther 2005 May 15; 21 (10): 1203-9 (Pubitemid 40733485)
57. Pace F, Porro GB. On-demand PPI therapy in GERD. Curr Treat Options Gastroenterol 2008 Feb; 11 (1): 35-42
58. Lobo FS, Wagner S, Gross CR, et al. Addressing the issue of channeling bias in observational studieswith propensity scores analysis. Res Social Adm Pharm 2006 Mar; 2 (1): 143-51 (Pubitemid 44144470)